No US "Christmas Tree Bill" For Rx User Fees

16 December 1996

Extension of the prescription drug user fee will be the first and top priority for the Food and Drug Administration when the new Congress convenes, Indiana's Democrat Governor Evan Bayh has told the Robertson Stephens & Co medical conference.

He told the Marketletter that while generally popular, the user-fee extension bill could get into trouble if it turned into a "Christmas Tree Bill," ie with many extra, often extraneous provisions attached, in hopes of getting them passed rather than jeopardize the original bill. Overall, he expects the Washington bipartisanship being discussed to prevail because "President Clinton is looking ahead to his historical legacy, and the Congress wants to survive to be re-elected in two years."

Gov Bayh warned industry to be particularly attentive to quality assurance issues because "they could have significant impact on industry while being politically attractive, even to Republicans." However, unlike the Administration's initial attempt at health care overhaul, he expects health care changes to be incremental.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight